Revenues - Additional Information (Detail) $ in Thousands	1 Months Ended				3 Months Ended	12 Months Ended
	Mar. 30, 2023	Jan. 31, 2020 USD ($)	Oct. 31, 2019 USD ($) FullTimeEquivalentServices	Mar. 31, 2019 USD ($) FullTimeEquivalentServices	Dec. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 Patients
Disaggregation of Revenue [Line Items]
Performance obligations remaining amount					$ 100	$ 100	$ 1,200
Revenue from performance obligations of the previous period recognized							0
Deferred Revenue					1,700	1,700	5,700
Milestone revenue upon closing of first patient with ARX305						$ 7,402	$ 7,455
Bigene Limited [Member]
Disaggregation of Revenue [Line Items]
Upfront payment received towards license fees				$ 10,000
Bigene Limited [Member] | Collaboration and Exclusive License Agreement [Member]
Disaggregation of Revenue [Line Items]
Notice period to be given by the counterparty for the termination of the license agreement				3 months
Bigene Limited [Member] | Collaboration and Exclusive License Agreement [Member] | Subsequent Event [Member]
Disaggregation of Revenue [Line Items]
Initial research term extension period	2 years
Novocodex [Member] | Development and Commercialization Agreement [Member]
Disaggregation of Revenue [Line Items]
Upfront payment received towards license fees			$ 2,000
Notice period to be given by the counterparty for the termination of the license agreement			6 months
Novocodex [Member] | Development and Commercialization Agreement [Member] | Point in Time [Member]
Disaggregation of Revenue [Line Items]
Milestone revenue upon closing of first patient with ARX305					$ 1,000
Sino Biopharmaceutical Limited [Member] | Development and Commercialization Agreement [Member]
Disaggregation of Revenue [Line Items]
Upfront payment received towards license fees		$ 10,000
Notice period to be given by the counterparty for the termination of the license agreement						6 months
Sino Biopharmaceutical Limited [Member] | Development and Commercialization Agreement [Member] | Phase One Clinical Trial for Products ARX Eight Twenty Two and Arx One Hundred and Two [Member]
Disaggregation of Revenue [Line Items]
Total number of patients for which the drug study detail is to be given by the counterparties | Patients								100
Minimum [Member]
Disaggregation of Revenue [Line Items]
Remaining performance obligations remaining satisfaction period					1 year	1 year
Minimum [Member] | Bigene Limited [Member] | Collaboration and Exclusive License Agreement [Member]
Disaggregation of Revenue [Line Items]
Number of full time equivalent services to be performed for receiving research and development related amount | FullTimeEquivalentServices				2
Minimum [Member] | Novocodex [Member] | Development and Commercialization Agreement [Member]
Disaggregation of Revenue [Line Items]
Number of full time equivalent services to be performed for receiving research and development related amount | FullTimeEquivalentServices			1
Maximum [Member]
Disaggregation of Revenue [Line Items]
Remaining performance obligations remaining satisfaction period					4 years	4 years
Maximum [Member] | Bigene Limited [Member] | Collaboration and Exclusive License Agreement [Member]
Disaggregation of Revenue [Line Items]
Number of full time equivalent services to be performed for receiving research and development related amount | FullTimeEquivalentServices				25